Abstract
Purpose
To define clinical and pathological factors predicting reclassification at the time of 1-year repeat biopsy (re-Bx) based on a Japanese cohort forming part of the Prostate Research International: Active Surveillance (PRIAS) study.
Patients and methods
The inclusion criteria for the PRIAS study are as follows: clinical stage T1c/T2, PSA ≤ 10 ng/ml, PSA density (PSAD) < 0.2 ng/ml per milliliter, one or two positive biopsy cores, and Gleason score (GS) ≤ 6 at initial diagnostic biopsy. Baseline clinical characteristics and prostate-specific antigen doubling time (PSADT) at the time of re-Bx were analyzed via multivariate logistic regression with respect to reclassification and ‘no cancer’ status on the 1-year re-Bx.
Results
A total of 386 patients were enrolled in PRIAS-JAPAN by the end of 2013. Of these, 216 underwent re-Bx at 1 year. A total of 73 patients (33.8 %) were reclassified, whereas 74 (34.3 %) had no cancer. Older age, a higher PSAD, a higher positive core rate, and a shorter PSADT were significant predictors of reclassification. The positive core rate was the predictor common to reclassification, no cancer, and high GS, upon re-Bx.
Conclusions
An interim analysis of a Japanese AS cohort participating in PRIAS revealed that the positive core rate was strongly associated with reclassification at the 1-year re-Bx. However, although amendment of the PRIAS inclusion criteria to incorporate a positive core might reduce any concern about underestimation, this would also reduce the number of patients undergoing AS.
Similar content being viewed by others
References
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69–90
Ito Y, Ioka A, Tanaka M, Nakayama T, Tsukuma H (2009) Trends in cancer incidence and mortality in Osaka, Japan: evaluation of cancer control activities. Cancer Sci 100:2390–2395
Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Berenguer A, Maattanen L, Bangma CH, Aus G, Villers A, Rebillard X, van der Kwast T, Blijenberg BG, Moss SM, de Koning HJ, Auvinen A, ERSPC Investigators (2009) Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360:1320–1328
Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Paez A, Maattanen L, Bangma CH, Aus G, Carlsson S, Villers A, Rebillard X, van der Kwast T, Kujala PM, Blijenberg BG, Stenman UH, Huber A, Taari K, Hakama M, Moss SM, de Koning HJ, Auvinen A, ERSPC Investigators (2012) Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 366:981–990
Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63:11–30
Fujimoto H, Nakanishi H, Miki T, Kubota Y, Takahashi S, Suzuki K, Kanayama HO, Mikami K, Homma Y (2011) Oncological outcomes of the prostate cancer patients registered in 2004: report from the Cancer Registration Committee of the JUA. Int J Urol 18:876–881
Hugosson J, Carlsson S, Aus G, Bergdahl S, Khatami A, Lodding P, Pihl CG, Stranne J, Holmberg E, Lilja H (2010) Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 11:725–732
Cooperberg MR, Broering JM, Kantoff PW, Carroll PR (2007) Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol 178:S14–S19
Lawrentschuk N, Klotz L (2011) Active surveillance for low-risk prostate cancer: an update. Nat Rev Urol 8:312–320
van den Bergh RC, Roemeling S, Roobol MJ, Roobol W, Schroder FH, Bangma CH (2007) Prospective validation of active surveillance in prostate cancer: the PRIAS study. Eur Urol 52:1560–1563
Bul M, Zhu X, Valdagni R, Pickles T, Kakehi Y, Rannikko A, Bjartell A, van der Schoot DK, Cornel EB, Conti GN, Boeve ER, Staerman F, Vis-Maters JJ, Vergunst H, Jaspars JJ, Strolin P, van Muilekom E, Schroder FH, Bangma CH, Roobol MJ (2013) Active surveillance for low-risk prostate cancer worldwide: the PRIAS study. Eur Urol 63:597–603
van den Bergh RC, Vasarainen H, van der Poel HG, Vis-Maters JJ, Rietbergen JB, Pickles T, Cornel EB, Valdagni R, Jaspars JJ, van der Hoeven J, Staerman F, Oomens EH, Rannikko A, Roemeling S, Steyerberg EW, Roobol MJ, Schroder FH, Bangma CH (2010) Short-term outcomes of the prospective multicentre ‘Prostate Cancer Research International: Active Surveillance’ study. BJU Int 105:956–962
Kakehi Y (2012) Active surveillance as a practical strategy to differentiate lethal and non-lethal prostate cancer subtypes. Asian J Androl 14:361–364
Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A (2010) Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 28:126–131
Sugimoto M, Shiraishi T, Tsunemori H, Demura T, Saito Y, Kamoto T, Kakehi Y (2010) Pathological findings at radical prostatectomy in Japanese prospective active surveillance cohort. Jpn J Clin Oncol 40:973–979
Kakehi Y, Kamoto T, Shiraishi T, Ogawa O, Suzukamo Y, Fukuhara S, Saito Y, Tobisu K, Kakizoe T, Shibata T, Fukuda H, Akakura K, Suzuki H, Shinohara N, Egawa S, Irie A, Sato T, Maeda O, Meguro N, Sumiyoshi Y, Suzuki T, Shimizu N, Arai Y, Terai A, Kato T, Habuchi T, Fujimoto H, Niwakawa M (2008) Prospective evaluation of selection criteria for active surveillance in Japanese patients with stage T1cN0M0 prostate cancer. Jpn J Clin Oncol 38:122–128
Bul M, Zhu X, Rannikko A, Staerman F, Valdagni R, Pickles T, Bangma CH, Roobol MJ (2012) Radical prostatectomy for low-risk prostate cancer following initial active surveillance: results from a prospective observational study. Eur Urol 62:195–200
Mitsuzuka K, Narita S, Koie T, Kaiho Y, Tsuchiya N, Yoneyama T, Kakoi N, Kawamura S, Tochigi T, Habuchi T, Ohyama C, Arai Y (2013) Pathological and biochemical outcomes after radical prostatectomy in men with low-risk prostate cancer meeting the Prostate Cancer International: Active Surveillance criteria. BJU Int 111:914–920
Bul M, van den Bergh RC, Rannikko A, Valdagni R, Pickles T, Bangma CH, Roobol MJ (2012) Predictors of unfavourable repeat biopsy results in men participating in a prospective active surveillance program. Eur Urol 61:370–377
Crawford ED (2009) Understanding the epidemiology, natural history, and key pathways involved in prostate cancer. Urology 73:S4–S10
Dall’Era MA, Albertsen PC, Bangma C, Carroll PR, Carter HB, Cooperberg MR, Freedland SJ, Klotz LH, Parker C, Soloway MS (2012) Active surveillance for prostate cancer: a systematic review of the literature. Eur Urol 62:976–983
Satkunasivam R, Kulkarni GS, Zlotta AR, Kalnin R, Trachtenberg J, Fleshner NE, Hamilton RJ, Jewett MA, Finelli A (2013) Pathological, oncologic and functional outcomes of radical prostatectomy following active surveillance. J Urol 190:91–95
Tosoian JJ, Trock BJ, Landis P, Feng Z, Epstein JI, Partin AW, Walsh PC, Carter HB (2011) Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol 29(16):2185–2190
Khatami A, Aus G, Damber JE, Lilja H, Lodding P, Hugosson J (2007) PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: results from the European randomized study of screening for prostate cancer, Sweden section. Int J Cancer 120:170–174
Whitson JM, Porten SP, Hilton JF, Cowan JE, Perez N, Cooperberg MR, Greene KL, Meng MV, Simko JP, Shinohara K, Carroll PR (2011) The relationship between prostate specific antigen change and biopsy progression in patients on active surveillance for prostate cancer. J Urol 185:1656–1660
Ross AE, Loeb S, Landis P, Partin AW, Epstein JI, Kettermann A, Feng Z, Carter HB, Walsh PC (2010) Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J Clin Oncol 28:2810–2816
Venkitaraman R, Norman A, Woode-Amissah R, Fisher C, Dearnaley D, Horwich A, Huddart R, Khoo V, Thompson A, Parker C (2007) Predictors of histological disease progression in untreated, localized prostate cancer. J Urol 178:833–837
San Francisco IF, Werner L, Regan MM, Garnick MB, Bubley G, DeWolf WC (2011) Risk stratification and validation of prostate specific antigen density as independent predictor of progression in men with low risk prostate cancer during active surveillance. J Urol 185:471–476
Briganti A, Chun FK, Suardi N, Gallina A, Walz J, Graefen M, Shariat S, Ebersdobler A, Rigatti P, Perrotte P, Saad F, Montorsi F, Huland H, Karakiewicz PI (2007) Prostate volume and adverse prostate cancer features: fact not artifact. Eur J Cancer 43:2669–2677
Hirama H, Sugimoto M, Ito K, Shiraishi T, Kakehi Y (2014) The impact of baseline [−2]proPSA-related indices on the prediction of pathological reclassification at 1 year during active surveillance for low-risk prostate cancer: the Japanese multicenter study cohort. J Cancer Res Clin Oncol 140(2):257–263
Acknowledgments
We thank Dr. Tomonori Habuchi, Dr. Takamitsu Inoue, Dr. Tadashi Matsuda, Dr. Hidefumi Kinoshita, Dr. Seiji Naito, Dr. Akira Yokomizo, Dr. Osamu Ogawa, Dr. Tomomi Kamba, Dr. Akito Terai, Dr. Kazuhiro Suzuki, Dr. Kazuto Ito, Dr. Yasuo Kitamura, Dr. Toshihiro Saito, Dr. Taiji Tsukamoto, Dr. Naoya Masumori, Dr. Hiroshi Kitamura, Dr. Tomohiko Ichikawa, Dr. Shinichi Sakamoto, Dr. Toshiro Terachi, Dr. Takeshi Nomoto, Dr. Koichiro Akakura, Dr. Yoshiko Maeda, Dr. Yukio Honma, Dr. Hiroshi Fukuhara, Dr. Hiroyoshi Suzuki, Dr. Naoto Kamiya, Dr. Yoichi Arai, Dr. Koji Mitsuzuka, Dr. Hiro-omi Kanayama, Dr. Tomoharu Fukumori, Dr. Hideki Sakai, Dr. Tsukasa Igawa, Dr. Seiichiro Ozono, Dr. Takayuki Sugiyama, Dr. Akio Matsubara, Dr. Jun Teishima, Dr. Toshiyuki Kamoto, Dr. Hiromasa Tsukino, Dr. Yoshihiko Tomita, Dr. Hisashi Kawazoe, Dr. Hideyasu Matsuyama, Dr. Hiroaki Matsumoto, Dr. Seiichi Saito, Dr. Takuma Oshiro, Dr. Isao Hara, and Dr. Takeshi Inagaki for their great contribution to this study. The authors thank all contributions for PRIAS-JAPAN.
Conflict of interest
None.
Ethical standard
This study has been approved by the appropriate ethics committee and has therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.
Author information
Authors and Affiliations
Consortia
Corresponding author
Rights and permissions
About this article
Cite this article
Sugimoto, M., Hirama, H., Yamaguchi, A. et al. Should inclusion criteria for active surveillance for low-risk prostate cancer be more stringent? From an interim analysis of PRIAS-JAPAN. World J Urol 33, 981–987 (2015). https://doi.org/10.1007/s00345-014-1453-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00345-014-1453-8